PALO ALTO, Calif., Aug. 22 CV Therapeutics, Inc.(Nasdaq: CVTX) announced today that eight abstracts, including a clinicaltrial update session on anti-arrhythmia data from the MERLIN TIMI-36 study,have been accepted for presentation at the European Society of Cardiology(ESC) Congress 2007 taking place in Vienna, Austria from September 1-5, 2007.
A clinical trial update session entitled, The Effect of Ranolazine, aNovel Anti-anginal Agent with Electrophysiologic Properties, on the Incidenceof Tachyarrhythmias: Results from the MERLIN-TIMI 36 Randomized ControlledTrial, is scheduled for presentation Wednesday, September 5 at 9:45 a.m.Central European Summer Time (CEST).
Clinical Outcomes in Patients with Diabetes or the Metabolic SyndromePresenting with Non- ST-elevation Acute Coronary Syndrome in the MERLIN- TIMI36 Trial; Poster, Sunday, September 2, 8:30 a.m.-12:30 p.m. CEST
Cost of Angina:
Recurrent Angina Following Revascularization - Frequency, PatientCharacteristics and Costs; Poster, Wednesday, September 5, 8:30 a.m. - 12:30p.m. CEST
Late Sodium Current:
Reduction of Repolarization Reserve Unmasks the Role of Late SodiumCurrent in Rabbit Isolated Hearts; Poster, Sunday, September 2, 8:30 a.m. -12:30 p.m. CEST
Mechanism of Ranolazine Block of Cardiac Na Channels; Poster, Monday,September 3, 2:00 - 6:00 p.m. CEST
Results from Two Randomized, Double-blind, Placebo-controlled TrialsEvaluating the Safety of Regadenoson in Patients with Reactive AirwaysDisease; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST
Side Effect Profile and Tolerability of Regadenoson Myocardial PerfusionScintigraphy in Women; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST
Superior Safety Profile of Regadenoson Versus Adenosine in Patients withChronic Obstructive Pulmonary Disease Undergoing Radionuclide MyocardialPerfusion Imaging; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST
In addition, on Tuesday, September 4, CV Therapeutics is sponsoring anEBAC (European Board for Accreditation in Cardiology) educational program,Targeting Myocardial Ischaemia-Future Opportunities for Improved Outcomes,chaired by Dr. Phillip Poole-Wilson of the United Kingdom and Dr. EugeneBraunwald of the United States. On Monday, September 3, CV Therapeutics issponsoring a FOCUS Cardiology Practice Session, Chronic Stable AnginaManagement.
Additional information regarding the ESC Congress 2007 can be accessed athttp://www.escardio.org
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is abiopharmaceutical company focused on applying molecular cardiology to thediscovery, development and commercialization of novel, small molecule drugsfor the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-releasetablets), is indicated for the treatment of chronic angina in patients whohave not achieved an adequate response with other antianginal drugs, andshould be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates andprograms include regadenoson, which is being developed for potential use as apharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonarydiseases. Regadenoson and CVT-6883 have not been determined by any regulatoryauthorities to be safe or effective in humans for any use.
Except for the historical information contained herein, the matters setforth in this press release are forward-looking statements within the meaningof the "safe harbor" provisions of the Private Securities Litigation ReformAct of 1995. These forward-looking statements are subject to risks anduncertainties that